vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Legacy Housing Corp (LEGH). Click either name above to swap in a different company.

Legacy Housing Corp is the larger business by last-quarter revenue ($25.5M vs $19.6M, roughly 1.3× STANDARD BIOTOOLS INC.). Legacy Housing Corp runs the higher net margin — 32.2% vs -177.4%, a 209.6% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -30.6%). Legacy Housing Corp produced more free cash flow last quarter ($15.7M vs $-23.1M). Over the past eight quarters, Legacy Housing Corp's revenue compounded faster (-9.1% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Legacy Housing Corp is a prominent U.S.-based manufacturer of affordable manufactured homes, tiny homes, and accessory dwelling units. It mainly caters to low- and middle-income consumers across North America, providing customizable residential solutions, supporting construction materials, and after-sales services for individual and community development clients.

LAB vs LEGH — Head-to-Head

Bigger by revenue
LEGH
LEGH
1.3× larger
LEGH
$25.5M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+19.1% gap
LAB
-11.5%
-30.6%
LEGH
Higher net margin
LEGH
LEGH
209.6% more per $
LEGH
32.2%
-177.4%
LAB
More free cash flow
LEGH
LEGH
$38.8M more FCF
LEGH
$15.7M
$-23.1M
LAB
Faster 2-yr revenue CAGR
LEGH
LEGH
Annualised
LEGH
-9.1%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
LEGH
LEGH
Revenue
$19.6M
$25.5M
Net Profit
$-34.7M
$8.2M
Gross Margin
48.5%
26.4%
Operating Margin
-168.5%
40.4%
Net Margin
-177.4%
32.2%
Revenue YoY
-11.5%
-30.6%
Net Profit YoY
-28.8%
-43.5%
EPS (diluted)
$-0.09
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
LEGH
LEGH
Q4 25
$25.5M
Q3 25
$19.6M
$28.8M
Q2 25
$21.8M
$38.4M
Q1 25
$40.8M
$24.3M
Q4 24
$36.7M
Q3 24
$22.1M
$30.2M
Q2 24
$22.5M
$31.7M
Q1 24
$45.5M
$30.8M
Net Profit
LAB
LAB
LEGH
LEGH
Q4 25
$8.2M
Q3 25
$-34.7M
$8.6M
Q2 25
$-33.5M
$14.7M
Q1 25
$-26.0M
$10.3M
Q4 24
$14.5M
Q3 24
$-26.9M
$15.8M
Q2 24
$-45.7M
$16.2M
Q1 24
$-32.2M
$15.1M
Gross Margin
LAB
LAB
LEGH
LEGH
Q4 25
26.4%
Q3 25
48.5%
20.2%
Q2 25
48.8%
32.4%
Q1 25
48.4%
29.2%
Q4 24
27.3%
Q3 24
54.9%
29.2%
Q2 24
46.1%
31.9%
Q1 24
53.1%
33.6%
Operating Margin
LAB
LAB
LEGH
LEGH
Q4 25
40.4%
Q3 25
-168.5%
33.7%
Q2 25
-118.1%
43.8%
Q1 25
-80.8%
47.7%
Q4 24
42.3%
Q3 24
-120.9%
50.8%
Q2 24
-134.5%
50.6%
Q1 24
-132.2%
54.3%
Net Margin
LAB
LAB
LEGH
LEGH
Q4 25
32.2%
Q3 25
-177.4%
30.0%
Q2 25
-153.7%
38.3%
Q1 25
-63.8%
42.3%
Q4 24
39.5%
Q3 24
-122.0%
52.4%
Q2 24
-203.3%
51.1%
Q1 24
-70.6%
49.1%
EPS (diluted)
LAB
LAB
LEGH
LEGH
Q4 25
$0.38
Q3 25
$-0.09
$0.35
Q2 25
$-0.09
$0.60
Q1 25
$-0.07
$0.41
Q4 24
$0.59
Q3 24
$-0.07
$0.64
Q2 24
$-0.12
$0.65
Q1 24
$-0.27
$0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
LEGH
LEGH
Cash + ST InvestmentsLiquidity on hand
$129.4M
$8.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$528.6M
Total Assets
$539.6M
$580.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
LEGH
LEGH
Q4 25
$8.5M
Q3 25
$129.4M
$13.6M
Q2 25
$158.6M
$2.6M
Q1 25
$150.9M
$3.4M
Q4 24
$1.1M
Q3 24
$210.6M
$570.0K
Q2 24
$269.8M
$60.0K
Q1 24
$287.1M
$621.0K
Total Debt
LAB
LAB
LEGH
LEGH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
LEGH
LEGH
Q4 25
$528.6M
Q3 25
$399.7M
$521.6M
Q2 25
$424.5M
$512.8M
Q1 25
$454.6M
$503.7M
Q4 24
$494.0M
Q3 24
$489.3M
$479.3M
Q2 24
$510.3M
$463.2M
Q1 24
$577.3M
$450.4M
Total Assets
LAB
LAB
LEGH
LEGH
Q4 25
$580.3M
Q3 25
$539.6M
$557.9M
Q2 25
$557.0M
$552.0M
Q1 25
$579.6M
$544.6M
Q4 24
$534.2M
Q3 24
$681.5M
$521.4M
Q2 24
$708.7M
$514.9M
Q1 24
$777.7M
$510.0M
Debt / Equity
LAB
LAB
LEGH
LEGH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
LEGH
LEGH
Operating Cash FlowLast quarter
$-22.2M
$19.0M
Free Cash FlowOCF − Capex
$-23.1M
$15.7M
FCF MarginFCF / Revenue
-118.1%
61.6%
Capex IntensityCapex / Revenue
4.5%
13.1%
Cash ConversionOCF / Net Profit
2.32×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$28.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
LEGH
LEGH
Q4 25
$19.0M
Q3 25
$-22.2M
$7.2M
Q2 25
$-20.7M
$6.1M
Q1 25
$-30.3M
$4.9M
Q4 24
$7.9M
Q3 24
$-27.9M
$13.8M
Q2 24
$-39.0M
$3.5M
Q1 24
$-62.5M
$10.8M
Free Cash Flow
LAB
LAB
LEGH
LEGH
Q4 25
$15.7M
Q3 25
$-23.1M
$5.1M
Q2 25
$-22.6M
$3.7M
Q1 25
$-35.3M
$3.6M
Q4 24
$6.0M
Q3 24
$-30.1M
$9.1M
Q2 24
$-41.0M
$1.7M
Q1 24
$-63.3M
$9.9M
FCF Margin
LAB
LAB
LEGH
LEGH
Q4 25
61.6%
Q3 25
-118.1%
17.8%
Q2 25
-103.6%
9.6%
Q1 25
-86.6%
15.0%
Q4 24
16.4%
Q3 24
-136.4%
30.2%
Q2 24
-182.2%
5.4%
Q1 24
-138.9%
32.2%
Capex Intensity
LAB
LAB
LEGH
LEGH
Q4 25
13.1%
Q3 25
4.5%
7.1%
Q2 25
8.7%
6.2%
Q1 25
12.4%
5.2%
Q4 24
5.1%
Q3 24
10.2%
15.6%
Q2 24
8.6%
5.5%
Q1 24
1.7%
2.8%
Cash Conversion
LAB
LAB
LEGH
LEGH
Q4 25
2.32×
Q3 25
0.83×
Q2 25
0.41×
Q1 25
0.48×
Q4 24
0.54×
Q3 24
0.88×
Q2 24
0.21×
Q1 24
0.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

LEGH
LEGH

Commercial Sales$8.6M34%
Retail Store Sales$6.0M24%
Inventory Finance Sales$5.0M20%
Direct Sales$4.4M17%
Other$1.5M6%

Related Comparisons